BioMerieux SA BIM

Morningstar Rating
€90.65 −1.25 (1.36%)
View Full Chart

Company Report

Price vs Fair Value

BIM is trading at a LOCK|rC&<#GN premium.
Price
€91.90
Fair Value
dl
Uncertainty
LOCK|%>xh
1-Star Price
LOCK|&.%
5-Star Price
LOCK|.@Y
Economic Moat
LOCK|X#<fF
Capital Allocation
LOCK|^hT!xv<

Bulls Say, Bears Say

Bulls

BioMérieux is a leader in niche markets, allowing the company to grow faster than the in vitro diagnostics market and shielding it from competing for market share with better-capitalized peers.

Bears

BioMérieux’s BioFire testing menu for molecular diagnostics is not well positioned for outpatient testing, giving competitors a chance to enter the market with more flexible testing panels.

Trading Information

Previous Close Price
€91.90
Day Range
€90.35–91.90
52-Week Range
€65.60–114.90
Bid/Ask
€90.20 / €93.00
Shares Outstanding
117.69M
Market Cap
€10.67B
Volume/Avg
149,595 / 166,734

Key Statistics

Price/Earnings (Normalized)
17.46
Price/Sales
2.73
Dividend Yield (Trailing)
1.07%
Dividend Yield (Forward)
1.07%
Dividend Payment Schedule
Jun
Total Yield
1.56%

Company Profile

BioMérieux designs, develops, and manufactures a broad portfolio of in vitro diagnostics for detecting disease-causing pathogens and contamination. The company operates in four segments: molecular biology (42% of 2024 sales), microbiology (33%), immunoassays (10%), and industrial applications (about 15%). The Americas account for the largest portion of the firm's revenue (40%), followed by Asia-Pacific (27%) and Europe, the Middle East, and Africa (27%). BioMérieux is headquartered in Marcy-l'Étoile, France.
Sector
Healthcare
Industry
Diagnostics & Research
Stock Style Box
Mid Core
Total Number of Employees
15,226

Competitors

Valuation

Metric
BIM
DIA
ABT
Price/Earnings (Normalized)
17.4628.9319.97
Price/Book Value
2.542.893.65
Price/Sales
2.733.973.88
Price/Cash Flow
12.4019.3017.97
Price/Earnings
BIM
DIA
ABT

Financial Strength

Metric
BIM
DIA
ABT
Quick Ratio
1.440.811.00
Current Ratio
2.301.791.45
Interest Coverage
38.687.377.30
Quick Ratio
BIM
DIA
ABT

Profitability

Metric
BIM
DIA
ABT
Return on Assets (Normalized)
9.12%—9.44%
Return on Equity (Normalized)
12.43%—18.30%
Return on Invested Capital (Normalized)
11.31%—12.90%
Return on Assets
BIM
DIA
ABT

Diagnostics & Research Industry Comparables

1-Day Chart
Name
Price
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
Thermo Fisher Scientific Inc
TMO
LOCK|T&c@ChNLOCK|bP%$256B
Danaher Corp
DHR
LOCK|w$pKG@>lLOCK|Sg$162B
IDEXX Laboratories Inc
IDXX
LOCK|wtJrZh@fLOCK|rQ$55B
Agilent Technologies Inc
A
LOCK|hQpd@B>@LOCK|wn$49B
Waters Corp
WAT
LOCK|rx&fY?LLOCK|#y>$45B
IQVIA Holdings Inc
IQV
LOCK|j?SCDWnLOCK|C%v?N$44B
Mettler-Toledo International Inc
MTD
LOCK|s#!^!hDjLOCK|?@!q$34B
Labcorp Holdings Inc
LH
LOCK|$pNXDGdLOCK|bm<S$30B
Illumina Inc
ILMN
LOCK|&K>@P>LOCK|lT^g$30B
Quest Diagnostics Inc
DGX
LOCK|S%#Kdg#LOCK|^G#&$29B

Sponsor Center